Drug profile

The FDA adverse-event record for Milbemycin Oxime And Praziquantel

45 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Milbemycin Oxime And Praziquantel. Species, reactions, and outcomes follow.

#1189 of 2,679
by report volume (all drugs)
45
adverse-event reports
4.4%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Milbemycin Oxime And Praziquantel ranks #1182 of 2679 by total reports (45). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1182
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Milbemycin Oxime And Praziquantel has 45 reports now versus 42 in that prior snapshot: 3 more (7.1%).

Report change
+3
Death-coded reports
+0
Death-coded share
−0.3 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Milbemycin Oxime And Praziquantel changes

Signature read: Milbemycin Oxime And Praziquantel's 4.4% death-coded share is among the lowest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
45
Total Reports
2
Deaths Reported
4.4%
Death-coded share of reports

Active Ingredients

Milbemycin Oxime And Praziquantel

Administration Routes

OralUnknown

Species Affected

Dog 45

Most Affected Breeds

Retriever - Labrador 9
Collie - Border 4
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 3
Dachshund (unspecified) 3
Retriever - Golden 2
Terrier - Jack Russell 2
Beagle 2
Boxer (German Boxer) 2
Terrier - Bull - American Pit 2
Pointing Dog - Hungarian Short-haired (Vizsla) 2

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 15
Vomiting 8
Lethargy (see also Central nervous system depression in 'Neurological') 5
Diarrhoea 5
Inappetence 4
Lethargy (see also Central nervous system depression in Neurological) 4
Medication error NOS 4
Ataxia 3
Intentional misuse 3
Panting 2
Pustules 2
Not eating 2

Outcome Breakdown

Ongoing
18 (40.0%)
Recovered/Normal
15 (33.3%)
Outcome Unknown
10 (22.2%)
Died
2 (4.4%)

Milbemycin Oxime And Praziquantel: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Milbemycin Oxime And Praziquantel (#1189 of 2,679 by report volume); death-coded 4.4%. PlainBreed drug row · death-coded share stamp 4.4% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →